MarketResearchNest.com adds “Tinnitus – Pipeline Review, H2 2017” new report to its research database. The report spread across in 63 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus – Pipeline Review, H2 2017, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.
Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260069
Report Highlights
The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
AudioCure Pharma GmbH, Auris Medical Holding AG, Knopp Biosciences LLC, Merz Pharma GmbH & Co KgaA, Otonomy Inc, Pragma Therapeutics SAS, SciFluor Life Sciences LLC, Sound Pharmaceuticals Inc
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260069
Featured News & Press Releases
May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study
Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback
Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus
Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update
Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus
Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus
Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus
Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City
Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260069
About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Contact Us
Mr. Jeet Jain
Sales Manager
USA: +1-240-284-8070
UK: +44-20-3290-4151
Your information will never be shared with any third party.